Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Cardiovascular events
Systematic review	5674 people with coronary stenting, cerebrovascular disease, or peripheral arterial disease; 3782 people (67%) with peripheral arterial disease 12 RCTs in this analysis	Occurrence of all cardiovascular events 12 to 144 weeks 289/3038 (10%) with cilostazol 328/2636 (12%) with placebo	RR 0.86 95% CI 0.74 to 0.99 P = 0.038	Small effect size	Cilostazol
Systematic review	5674 people with coronary stenting, cerebrovascular disease, or peripheral arterial disease; 3782 people (67%) with peripheral arterial disease 12 RCTs in this analysis	Occurrence of cerebrovascular events 12 to 144 weeks 67/3038 (2%) with cilostazol 111/2636 (4%) with placebo	RR 0.58 95% CI 0.43 to 0.78 P <0.001	Small effect size	Cilostazol
Systematic review	5674 people with coronary stenting, cerebrovascular disease, or peripheral arterial disease; 3782 people (67%) with peripheral arterial disease 12 RCTs in this analysis	Occurrence of cardiac events 12 to 144 weeks 222/3038 (7%) with cilostazol 217/2636 (8%) with placebo	RR 0.99 95% CI 0.83 to 1.17 P = 0.908		Not significant